Combined molecular targets of cabozantinib and vemurafenib

The combined molecular targets of cabozantinib and vemurafenib represent a therapeutic strategy aimed at inhibiting both the primary oncogenic driver and the bypass resistance mechanisms in various cancers. Cabozantinib is a multi-kinase inhibitor that targets MET (Hepatocyte Growth Factor Receptor), VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), and AXL, which are essential for tumor growth, angiogenesis, and the development of resistance to targeted therapies (Yakes et al., 2011, PMID: 21933810). Vemurafenib is a selective inhibitor of the BRAF V600E mutation, which drives constitutive MAPK pathway signaling in approximately 50% of melanomas (Bollag et al., 2010, PMID: 20818324). The combination of these targets is particularly relevant in the context of BRAF-inhibitor resistance, where MET and AXL signaling often provide alternative survival signals to the cancer cell (Straussman et al., 2012, PMID: 22763442). By inhibiting these pathways concurrently, the combination seeks to prevent or overcome adaptive resistance and improve clinical outcomes in patients with BRAF-mutant malignancies. This multi-target approach addresses the complexity of tumor signaling networks by blocking both the intracellular kinase cascade and the cell-surface receptors that can reactivate it. Clinical trials have explored this combination to evaluate its efficacy in overcoming HGF-mediated resistance in BRAF-mutant melanoma and other solid tumors (ClinicalTrials.gov). Notable safety concerns for this combination include hypertension, secondary skin cancers, and potential hepatotoxicity (NIH, LiverTox; StatPearls).

Other names

MET/VEGFR2/AXL/BRAF V600E kinase profileCabozantinib and Vemurafenib target setMulti-kinase and BRAF inhibition profile

Simultaneous inhibition of multiple receptor tyrosine kinases (MET, VEGFR, AXL) and the BRAF V600E mutant kinase to block downstream MAPK/ERK and PI3K/AKT signaling pathways.